MTHFR and nitric oxide: the missing element

By Jeff Butterworth N.D — Specialist Naturopath · 30 years in clinical practice

If you have an MTHFR variant you've probably been told to take methylfolate and B12. Here's the half of the story nobody mentions — how MTHFR quietly lowers nitric oxide, why that explains so many of the symptoms, and how to restore it.

Somewhere in the last ten years, MTHFR became the gene everyone had heard of. A genetic test comes back, the letters C677T or A1298C appear, and a story begins: you can't methylate properly, you need methylfolate, you need methyl-B12, avoid folic acid, and you'll feel better.

Some people do. A great many don't. In thirty years of practice I have seen hundreds of people with MTHFR variants who have done everything the internet told them — the active B vitamins, the clean diet, the careful avoidance of synthetic folate — and who still wake unrefreshed, still get the afternoon slump, still have the cold hands, the migraines, the blood pressure that creeps, the low mood that won't quite lift. They've fixed the supply side of methylation. What nobody told them about is delivery.

That is what this article is about. MTHFR variants don't just affect folate. Through a chain of biochemistry that has been sitting in the cardiovascular literature for two decades, they reduce your body's supply of nitric oxide — the molecule that opens your blood vessels and carries oxygen and nutrients to every tissue you own. And nitric oxide, it turns out, is the thing your body uses to neutralise the very toxin MTHFR variants produce.

I believe this is the missing element. Let me build the case properly.

Part one — what MTHFR actually is

The enzyme

MTHFR stands for methylenetetrahydrofolate reductase. It is an enzyme — a protein that does one job — and the job is to convert one form of folate (5,10-methylenetetrahydrofolate) into the active form your body uses for methylation: 5-methyltetrahydrofolate, or 5-MTHF, the compound sold as "methylfolate".

Methylation is your body's tagging system. Attaching a methyl group (one carbon, three hydrogens) to a molecule switches it on or off: it's how you make and break down neurotransmitters like dopamine and adrenaline, how you regulate which genes are read, how you process oestrogen and histamine, how you build creatine and phosphatidylcholine, and how you recycle homocysteine.

That last one matters most for this article. Homocysteine is an amino acid produced every time your body uses a methyl group. It is toxic to blood vessels in excess, so the body recycles it back to methionine — and the methyl group it uses to do that comes from 5-MTHF, with vitamin B12 as the co-worker. Less MTHFR activity means less 5-MTHF, which means homocysteine can accumulate. That is the central biochemical fact of MTHFR variants, and everything in this article flows from it.

The variants

Two common variants have been studied in depth.

These variants are common. Around 30–40% of people of European descent carry at least one 677T allele; 8–15% are TT, rising to 20–25% in Mediterranean, Hispanic and some East Asian populations and falling to a few per cent in people of African descent [2]. Because A1298C is also common, a large minority of any waiting room is carrying some reduction in MTHFR activity. This is not a rare disorder. It is a normal human variation that matters more in the modern environment than it did in the one we evolved in.

Why the same genotype looks different in different people

This is the nuance the internet skips. Two people can carry the identical TT genotype and have completely different biochemistry. What decides which way it goes:

• Folate intake. The TT enzyme works well enough when it is saturated with folate and works poorly when it isn't. Homocysteine in TT carriers is dramatically higher when folate status is low and close to normal when it is high [3].

• Riboflavin (vitamin B2). The 677T enzyme's defect is that it drops its FAD cofactor — and FAD is made from riboflavin. Supplying riboflavin stabilises the enzyme. In randomised trials from the University of Ulster, riboflavin alone lowered homocysteine and, remarkably, blood pressure — but only in people with the TT genotype [4, 5]. Hold on to that finding; we'll come back to it.

• Vitamin B12 and B6. B12 is the co-worker in the homocysteine-to-methionine step; B6 runs the alternative "drain" (transsulfuration) that turns homocysteine into cysteine and glutathione. Low B12 in a TT carrier is a very different situation from adequate B12.

• Choline and betaine. The liver has a second, folate-independent way to recycle homocysteine, using betaine from choline. Eggs, liver and beetroot supply it. People eating a low-choline diet lean harder on the MTHFR route.

• Oxidative stress, alcohol and inflammation. The thermolabile enzyme is more sensitive to all three. Heavy drinking, smoking, chronic inflammation and poor sleep all worsen expression.

• Age and hormones. Homocysteine rises with age in everyone; oestrogen lowers it, which is one reason women often notice MTHFR-related symptoms emerging or worsening through perimenopause and after.

• Other genes. MTR, MTRR, CBS, COMT and the nitric oxide synthase gene itself (NOS3) all modify the picture. A single MTHFR result is one card in a hand.

The practical point: MTHFR variants describe a tendency, not a destiny — and the things that decide how the tendency expresses are, for the most part, things you control.

How it shows up

There is a long and sometimes over-enthusiastic list of conditions associated with MTHFR variants. The ones with the strongest evidence and the ones I see most often in practice cluster into recognisable themes:

• Cardiovascular. Elevated homocysteine is an independent marker of vascular risk, and the TT genotype is over-represented in "H-type" hypertension — high blood pressure with high homocysteine [6, 7]. Even in healthy adults, the TT genotype is associated with higher blood pressure and stiffer central arteries [8].

• Circulation. Cold hands and feet, slow recovery from exercise, easy muscle fatigue. Rarely the presenting complaint, almost always present when you ask.

• Neurological. Migraine — particularly migraine with aura — has one of the more consistent associations with C677T. Brain fog, poor word recall and a feeling that thinking is "effortful" are common reports.

• Mood. Low mood, anxiety and poor stress tolerance. Methylation builds and clears neurotransmitters, and — as we'll see — the same cofactor that limits nitric oxide production also limits dopamine and serotonin synthesis.

• Energy. A tiredness that isn't fixed by sleep and that tracks with poor circulation and poor oxygen delivery.

• Reproductive. Neural tube defect risk is the best-established association, and the reason folate is recommended around conception. Some studies link the variants to pregnancy loss and pre-eclampsia, with mixed results.

• The methylfolate paradox. Many people feel worse on methylfolate — wired, anxious, unable to sleep, headachy. They are told they are "over-methylating". Often, in my experience, what they are actually experiencing is a sudden surge of supply into a system whose delivery side has not been prepared.

If you recognise yourself in three or four of those, keep reading. This is where the story gets interesting.

Part two — the connection nobody talks about: MTHFR and nitric oxide

What nitric oxide does

Nitric oxide (NO) is a gas made in the lining of your blood vessels. Its job is to tell the vessel wall to relax. A relaxed vessel is a wider vessel, carrying more blood, oxygen and nutrients to every tissue downstream: heart, brain, muscle, gut, skin, the glands that make your hormones. NO governs blood pressure, circulation, stamina, recovery, memory, sexual function and the efficiency of your mitochondria. If one molecule sits at the centre of healthy ageing, this is it — and by around 40 most adults make roughly half what they did at 20.

The enzyme that makes it, endothelial nitric oxide synthase (eNOS), is a fussy machine. It needs the amino acid L-arginine as raw material and a cofactor called tetrahydrobiopterin (BH4) to hold it in the right shape. Without enough BH4, the enzyme "uncouples": it stops making NO and starts making superoxide — a free radical — instead. Uncoupled eNOS is one of the central mechanisms of vascular ageing.

Now watch what MTHFR variants do to that machine.

Mechanism one: homocysteine blocks the enzyme

Homocysteine raises levels of a compound called ADMA — asymmetric dimethylarginine. ADMA is arginine's evil twin: it sits in the enzyme's active site and stops it working. Homocysteine does this by disabling DDAH, the enzyme that normally clears ADMA away. In a landmark paper in Circulation, John Cooke's group at Stanford showed that homocysteine impairs the nitric oxide synthase pathway precisely through this ADMA route, and that the effect could be reversed by antioxidants [9].

So the very metabolite that MTHFR variants allow to accumulate is an inhibitor of nitric oxide production.

Mechanism two: low 5-MTHF uncouples the enzyme

This is the most elegant part of the story. 5-MTHF — the active folate that MTHFR variants under-produce — has a second job that has nothing to do with methylation. It supports the recycling of BH4, the cofactor eNOS needs to stay coupled, and it directly scavenges the peroxynitrite that destroys BH4.

In 2006, Antoniades and colleagues at Oxford took blood vessels from patients undergoing bypass surgery and showed that 5-MTHF rapidly improved vessel function, increased vascular BH4, reduced superoxide production and recoupled eNOS — in human tissue, within hours [10]. Earlier work had shown the same interaction between 5-MTHF and BH4 in living people [11].

Less MTHFR activity means less 5-MTHF, which means less BH4 support, which means an eNOS enzyme that is more likely to be uncoupled — producing free radicals instead of nitric oxide. The gene that limits your methylation also limits the coupling of your nitric oxide enzyme.

Mechanism three: oxidative stress destroys the NO you do make

Homocysteine generates superoxide as it auto-oxidises. Superoxide reacts with nitric oxide almost instantly to form peroxynitrite — a molecule that is both toxic to vessels and a destroyer of BH4. So homocysteine doesn't just reduce production; it also shortens the life of every NO molecule you manage to produce, and in the process degrades the cofactor you needed for the next one. This is a loop, and loops are what turn a mild genetic tendency into a chronic symptom picture.

Mechanism four: nitric oxide is how your body detoxifies homocysteine

Here is the piece that turns the whole story around. Nitric oxide is not just a victim of homocysteine. It is the body's front-line defence against it.

In 1993, Jonathan Stamler's group at Harvard showed that healthy endothelium protects itself from homocysteine by reacting it with nitric oxide to form S-nitroso-homocysteine — a compound that is not toxic to vessels, does not generate free radicals, and is in fact a vasodilator [12]. As long as NO is abundant, homocysteine is neutralised on contact. When NO falls, homocysteine's toxicity is unopposed.

Think about what that means for someone with an MTHFR variant. They produce more homocysteine. Homocysteine lowers NO. Lower NO means less capacity to neutralise homocysteine. Their defence against their own biochemistry is the very thing their biochemistry erodes. Nitric oxide is not one item on a list of things to support. It is the fulcrum.

Mechanism five: the shared cofactor that explains the mood and energy

BH4 has one more job. It is the cofactor not only for nitric oxide synthase but for tyrosine hydroxylase and tryptophan hydroxylase — the enzymes that begin the synthesis of dopamine, noradrenaline and serotonin. When BH4 is depleted by the oxidative load of high homocysteine, the same shortage that limits NO also limits the neurotransmitters that govern motivation, mood and sleep. This is why the MTHFR symptom cluster looks the way it does — cold hands and low mood and fatigue and brain fog — and why supporting BH4 and NO can shift things that methylfolate alone never touched.

The human evidence

None of this is theoretical. The riboflavin trials I mentioned earlier are, in my reading, the clearest demonstration in the literature. Riboflavin stabilises the 677T enzyme. In people with the TT genotype and high blood pressure, riboflavin alone lowered systolic pressure by around 6–13 mmHg in randomised trials — a blood-pressure effect from a B vitamin, seen only in the genotype whose enzyme it repairs [4, 5]. Blood pressure is a nitric oxide phenomenon. Repair the enzyme, restore the folate, recouple eNOS, and the vessels relax. The TT genotype is also associated with higher blood pressure and less favourable central haemodynamics in otherwise healthy adults, well before any diagnosis [8] — the vascular effect is present early, in people who feel fine, which is exactly the population that gets told their MTHFR result "doesn't mean anything".

Part three — why optimising nitric oxide is the foundational intervention

I want to be precise about the word foundational. I don't mean "important" or "also worth doing". I mean the thing that has to be in place for the other things to work.

First, because delivery precedes supply. Methylfolate, B12, riboflavin, choline — every cofactor in the MTHFR conversation has to travel through blood vessels to reach the tissues that need it. Stiff, constricted, NO-poor vessels deliver less of everything. This is why people can take the right nutrients and still feel nothing.

Second, because NO is the antidote. As Stamler showed, abundant nitric oxide neutralises homocysteine on contact. Restoring NO doesn't just improve circulation; it directly reduces the damage the MTHFR variant is causing.

Third, because there is a second pathway that your genes cannot touch. Everything above concerns the enzymatic pathway — eNOS, BH4, arginine, ADMA — the pathway MTHFR variants compromise. But your body has a second, entirely independent route to nitric oxide: the nitrate–nitrite–NO pathway. Dietary nitrates from beetroot, rocket and leafy greens are absorbed, concentrated in saliva, converted to nitrite by bacteria on the tongue, and then to nitric oxide in the stomach and blood. This pathway needs no eNOS, no BH4, no arginine and no folate [13]. It is, in the most literal sense, genotype-proof. For someone whose enzymatic pathway is compromised by MTHFR biochemistry, it is the back door — and most people with MTHFR variants have never been told it exists.

Fourth, because the enzymatic pathway can be recoupled. Vitamin C stabilises BH4 and restores eNOS coupling in human endothelium [14]. L-citrulline raises arginine levels and, critically, raises the arginine-to-ADMA ratio — pushing the ADMA blocker out of the enzyme's active site. Antioxidants protect the NO you make from superoxide. So the compromised pathway can be substantially rescued at the same time as the independent pathway is opened.

Fifth, because it can be measured. A saliva nitric oxide strip reads your nitrite status in fifteen seconds. Optimal is 220–435 mg/L, sweet spot around 350. For someone with an MTHFR variant, I would put this test alongside homocysteine as the two numbers that matter most — one tells you how much of the toxin you are making, the other tells you how much of the antidote you have.

There is one nuance worth stating, because the science is honest about it. In cell studies, very high levels of nitric oxide can inhibit methionine synthase, the B12-dependent enzyme in the homocysteine cycle [15]. This is not an argument against restoring NO — those are supraphysiological concentrations, and the physiological restoration we're aiming for is what protects the cycle, not what inhibits it. It is an argument for doing it the way the body does it: food-based nitrates, moderate citrulline, tested into the optimal range, rather than megadosing. Optimise, don't flood.

Part four — how to do it with Ultimate 4

I formulated Ultimate 4 as a nitric-oxide foundation for adults over 40. I did not formulate it for MTHFR. But when I lay its ingredients against the five mechanisms above, it covers the ground more completely than anything I could have designed for the purpose — because it works both pathways at once and protects the result.

One scoop, each morning, in water. On the days you test, test before it.

The pattern I use in practice

1. Test. Nitric oxide saliva strip on waking, before eating, drinking or brushing. Ask your GP for a homocysteine level with your next bloods (fasting; optimal is under 8 µmol/L, not just "in range").

2. Open the second pathway. Ultimate 4 every morning, plus one serve of nitrate-rich greens at lunch and dinner. The beautiful coincidence here is that the nitrate-richest leaves — rocket, spinach, bok choy — are also among the folate-richest. The same salad feeds both pathways.

3. Protect the pathway. Retire antibacterial mouthwash and antiseptic toothpaste — they kill the tongue bacteria the second pathway depends on, and in one study raised blood pressure within days [16]. Breathe through your nose; hum on the out-breath.

4. Keep your cofactors — with a practitioner. Methylfolate, methyl- or hydroxy-B12, riboflavin (the TT enzyme's stabiliser), B6, and choline from eggs. These are the supply side. They belong in the plan. They simply work better once delivery is restored, and in my experience people tolerate them far better after two to three weeks of nitric oxide support than before.

5. Move. Exercise is the strongest natural stimulus for eNOS your body has. A daily walk is part of the dose; strength work twice a week.

6. Retest at week 4 and week 12. NO strip trend, home blood pressure, and homocysteine at week 12. Expect the strip to move first, then blood pressure, then the way you feel on your cofactors.

Full details, the daily routine and a printable tracker are in the MTHFR nitric oxide protocol at butterworthhealth.com/pages/protocols. You need to be a customer to access this protocol

What I tell people with MTHFR now

You were told your problem was a methylation problem. It is — but only half of it. The other half is a delivery problem, a defence problem, and a cofactor problem, all of which come back to one molecule that nobody in the MTHFR conversation was talking about.

Restore nitric oxide first. Feed the pathway your genes can't limit. Recouple the one they can. Give your body back the antidote to its own homocysteine. Then add the cofactors, and notice how differently they land.

That's the missing element. It has been sitting in the cardiovascular journals for thirty years, waiting for someone to connect it to the people it applies to.

— Jeff

If you want to learn more about Nitric oxide optimisation join my community 

https://www.facebook.com/groups/butterworthhealthoptimisation

This article is educational and does not replace individual medical advice. Supplements support healthy function; they do not treat, cure or prevent any disease. MTHFR variants and homocysteine should be assessed and managed with your healthcare practitioner. If you take prescription medication, are pregnant or breastfeeding, or manage a health condition, speak with your healthcare provider before changing your supplement routine.

References

1. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111–113.

2. Wilcken B, Bamforth F, Li Z, et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet. 2003;40(8):619–625.

3. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93(1):7–9.

4. Horigan G, McNulty H, Ward M, Strain JJ, Purvis J, Scott JM. Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFR. J Hypertens. 2010;28(3):478–486.

5. Wilson CP, McNulty H, Ward M, et al. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension. 2013;61(6):1302–1308.

6. Liao Y, et al. Association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and H-type hypertension: a systematic review and meta-analysis. Ann Hum Genet. 2022;86(5):278–289.

7. Homocysteine levels, H-hypertension, and the MTHFR C677T genotypes: a complex interaction. Heliyon. 2023;9(6):e16111.

8. Rooney M, et al. Impact of the MTHFR C677T polymorphism on blood pressure and related central haemodynamic parameters in healthy adults. J Hum Nutr Diet. 2022;35(4):689–700.

9. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104(21):2569–2575.

10. Antoniades C, Shirodaria C, Warrick N, et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 2006;114(11):1193–1201.

11. Verhaar MC, Wever RM, Kastelein JJ, et al. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 1998;97(3):237–241; and Hyndman ME, et al. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol. 2002;282(6):H2167–H2172.

12. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91(1):308–318.

13. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7(2):156–167.

14. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem. 2001;276(1):40–47.

15. Danishpajooh IO, Gudi T, Chen Y, Kharitonov VG, Sharma VS, Boss GR. Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway. J Biol Chem. 2001;276(29):27296–27303.

16. Kapil V, Haydar SM, Pearl V, Lundberg JO, Weitzberg E, Ahluwalia A. Physiological role for nitrate-reducing oral bacteria in blood pressure control. Free Radic Biol Med. 2013;55:93–100.

17. McNulty H, Dowey le RC, Strain JJ, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation. 2006;113(1):74–80.

18. Schwedhelm E, Maas R, Freese R, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. 2008;65(1):51–59.